ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)

China · Delayed Price · Currency is CNY

9.19

+0.10 (1.10%)

Sep 30, 2026, 3:04 PM CST

Market Cap	2.36B -11.4%
Revenue (ttm)	849.67M +3.8%
Net Income	28.76M +217.1%
EPS	0.12 +205.2%
Shares Out	257.21M
PE Ratio	79.80
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,486,300
Open	9.00
Previous Close	9.09
Day's Range	9.00 - 9.30
52-Week Range	6.93 - 15.20
Beta	0.46
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2026

About SHE:300254

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, smoking cessation drugs, pediatric drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, nephropathy drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2005

Employees 1,162

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300254

Full Company Profile

Financial Performance

In 2025, SHE:300254's revenue was 870.79 million, an increase of 2.86% compared to the previous year's 846.61 million. Earnings were 24.85 million, a decrease of -41.10%.

Financial Statements